KellyAnneSmuckerMD

PubMed

• 113 citations
  Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
  Samantha Jaglowski, Jeffrey A. Jones, Veena Nagar, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Jennifer A. Woyach, Kristie A. Blum, Michael R. Grever, Kell...> ;Blood. 2015 Aug 13
• 217 citations
  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
  Jennifer A. Woyach, Kelly A. Smucker, Lisa L. Smith, Arletta Lozanski, Yiming Zhong, Amy S. Ruppert, David M. Lucas, Katie L. Williams, Weiqiang Zhao, Laura Z. Rassent...> ;Blood. 2014 Mar 20
• 159 citations
  Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
  Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew R. Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jes...> ;Blood. 2014 Feb 20
• 593 citations
  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
  Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn Lar...> ;Blood. 2013 Oct 10
• Join now to see all